Classifying severity of cystic fibrosis lung disease using longitudinal pulmonary function data

American Journal of Respiratory and Critical Care Medicine

Volumn 174, Issue 7, 2006, Pages 780-786

  Schluchter, Mark D ^a   Konstan, Michael W ^b   Drumm, Mitchell L ^b   Yankaskas, James R ^b   Knowles, Michael R ^b  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b NONE

Author keywords

Association studies; FEV1; Genetic modifiers

Indexed keywords

ADOLESCENT; ADULT; ARTICLE; CONTROLLED STUDY; CYSTIC FIBROSIS; DEMOGRAPHY; DISEASE CLASSIFICATION; DISEASE SEVERITY; FEMALE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; HOMOZYGOSITY; HUMAN; LOGISTIC REGRESSION ANALYSIS; LUNG DISEASE; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; SCHOOL CHILD; SURVIVAL RATE;

ADOLESCENT; ADULT; CHILD; CYSTIC FIBROSIS; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; LEAST-SQUARES ANALYSIS; LOGISTIC MODELS; MALE; PHENOTYPE; POLYMORPHISM, GENETIC; ROC CURVE; SEVERITY OF ILLNESS INDEX;

EID: 33749446228     PISSN: 1073449X     EISSN: 1073449X     Source Type: Journal    
DOI: 10.1164/rccm.200512-1919OC     Document Type: Article

References (23)

1. Kerem E, Reisman J, Corey M, Canny GJ, Levison H. Prediction of mortality in patients with cystic fibrosis. N Engl J Med 1992;327:1244-1255.
2. Schluchter MD, Konstan MW, Davis PB. Jointly modelling the relationship between survival and pulmonary function in cystic fibrosis patients. Stat Med 2002;21:1271-1287.
3. Corey M, Edwards L, Levison H, Knowles M. Longitudinal analysis of pulmonary function decline in patients with cystic fibrosis. J Pediatr 1997;131:809-814.
4. Kerem E, Corey M, Kerem BS, Rommens J, Markiewicz D, Levison H, Tsui LC, Durie P. The relation between genotype and phenotype in cystic fibrosis: analysis of the most common mutation (delta F508). N Engl J Med 1990;323:1517-1522.
5. Newton-Chen C, Hirschhorn JN. Genetic association studies of complex traits: design and analysis issues. Mutat Res 2005;573:54-69.
6. Wang WY, Barratt BJ, Clayton DG, Todd JA. Genome-wide association studies: theoretical and practical concerns. Nat Rev Genet 2005;6:109-118.
7. Cutting GR. Modifier genetics: cystic fibrosis. Annu Rev Genomics Hum Genet 2005;6:237-260.
8. Sontag MK, Accurso FJ. Gene modifiers in pediatrics: application to cystic fibrosis. Adv Pediatr 2004;51:5-36.
9. Corey ML. Longitudinal studies in cystic fibrosis. In: Sturgess JM, editor. Perspectives in cystic fibrosis: proceedings of the 9th international congress on cystic fibrosis. Toronto, Ontario: Canadian Cystic Fibrosis Foundation; 1980. pp. 246-255.
10. Davis PB. Clinical pathophysiology and manifestations of lung disease. In: Yankaskas JR, Knowles MR, editors. Cystic fibrosis in adults. Philadelphia: Lippincott-Raven; 1999. pp. 45-67.
11. Gordon D, Finch SJ. Factors affecting statistical power in the detection of genetic association. J Clin Invest 2005;115:1408-1418.
12. Drumm ML, Konstan MW, Schluchter MD, Handler A, Pace R, Zou F, Zariwala M, Fargo D, Xu A, Dunn JM, et al. Genetic modifiers of lung disease in cystic fibrosis. N Engl J Med 2005;353:1443-1453.
13. U.S. Cystic Fibrosis Foundation. Patient registry 1999 annual data report. Bethesda, MD: Cystic Fibrosis Foundation; 2000.
14. Knudson RJ, Lebowitz MD, Holberg CJ, Burrows B. Changes in the normal maximal expiratory flow-volume curve with growth and aging. Am Rev Respir Dis 1983;127:725-734.
15. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982;143:29-36.
16. SAS Institute, Inc. SAS/STAT 9.1 User's guide. Cary, NC: SAS Institute, Inc.; 2004.
17. Burrows B, Lebowitz MD, Camilli AE, Knudson RJ. Longitudinal changes in FEV1 in adults: methodologic considerations and findings in healthy nonsmokers. Am Rev Respir Dis 1986;133:974-980.
18. Schlesselman JJ. Planning a longitudinal study: II. Frequency of measurement and study duration. J Chronic Dis 1973;26:561-570.
19. Wu MC. Sample size for comparison of changes in the presence of right censoring caused by death, withdrawal, and staggered entry. Control Clin Trials 1988;9:32-46.
20. Davis PB, Byard PJ, Konstan MW. Identifying treatments that halt progression of pulmonary disease in cystic fibrosis. Pediatr Res 1997;41:161-165.
21. Mekus F, Laabs U, Veeze H, Tummler B. Genes in the vicinity of CFTR modulate the cystic fibrosis phenotype in highly concordant or discordant F508del homozygous sib pairs. Hum Genet 2003;112:1-11.
22. Kulich M, Rosenfeld M, Campbell J, Kronmal R, Gibson RL, Goss CH, Ramsey B. Disease-specific reference equations for lung function in patients with cystic fibrosis. Am J Respir Crit Care Med 2005;172:885-891.
23. Littell R, Milliken G, Stroup W, Wolfinger R. SAS System for Mixed Models. Cary, NC: SAS Institute; Inc., 1996.